Story perspectives

Breakthroughs in Myeloma Treatment Show Promising Patient Outcomes

8/30/2025

24 5

Summary

Story summary

Hamza Hashmi reported on August 28, 2025, that immune MRD negativity in myeloma patients predicts long-term disease control without altering therapy.
Robert Orlowski presented a study on August 29, 2025, revealing that BCMA-directed CAR-T therapy for plasma cell leukemia achieved a median progression-free survival of 9 months and overall survival of 13 months.
Both insights highlight significant advancements in myeloma treatment and improved patient outcomes.

1 of 1

Story summary

Hamza Hashmi reported on August 28, 2025, that immune MRD negativity in myeloma patients predicts long-term disease control without altering therapy.
Robert Orlowski presented a study on August 29, 2025, revealing that BCMA-directed CAR-T therapy for plasma cell leukemia achieved a median progression-free survival of 9 months and overall survival of 13 months.
Both insights highlight significant advancements in myeloma treatment and improved patient outcomes.